Esquema de Manejo Quirúrgico para Tumores del Estroma Gastrointestinal

El seguimiento se debe llevar a cabo según las recomendaciones de las guías de la NCCN, es decir, con TC abdominal con contraste cada seis meses durante cinco años y después anualmente, para los pacientes de riesgo intermedio o alto, tal como se hizo en el paciente sometido a deri­vación gástrica en esta serie; sin embargo, a los pacientes clasificados como de muy bajo riesgo se les puede hace un seguimiento más espacia­do, como en los dos sometidos a manga gástrica. Con lo anterior, nos permitimos proponer un algoritmo de manejo para este tipo de tumores hallados de forma incidental durante la cirugía bariátrica (figura 3) 31.

Conclusiones

El manejo laparoscópico de los tumores del es­troma gastrointestinal de 2 o más cm de diáme­tro encontrados durante un procedimiento de cirugía bariátrica, es posible teniendo en cuenta su ubicación, obteniendo márgenes libres de en­fermedad tumoral, baja morbilidad, ausencia de mortalidad, sin aumento en la estancia hospita­laria y garantizando una supervivencia libre de enfermedad en todos los pacientes.

Conflicto de intereses. Los autores no tienen potencial conflicto de intereses con respecto a la publicación de este documento.

Referencias

1. Chiappetta S, Theodoridou S, Stier C, Weiner R. Incidental finding of GIST during obesity surgery. Obes Surg. 2015;25:579-83.
2. Nguyen NT, Nguyen B, Gebhart A, Hohmann S. Changes in the makeup of bariatric surgery: A national in-crease in use of laparoscopic sleeve gastrectomy. J Am Coll Surg. 2013;216:252-7.
3. Tran T, Dávila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100:162-8.
4. Yuval JB, Khalaileh A, Abu-Gazala M, Shachar Y, Keidar A, Mintz Y, et al. The true incidence of gastric GIST—a study based on morbidly obese patients undergoing sleeve gastrectomy. Obes Surg. 2014;24:2134-7.
5. Sánchez BR, Morton JM, Curet MJ, Alami RS, Safadi BY. Incidental finding of gastrointestinal stromal tu-mors (GISTs) during laparoscopic gastric bypass. Obes Surg. 2005;15:1384-8.
6. Crouthamel M, Kaufman J, Billing J, Billing P, Landerholm R. Incidental gastric mesenchymal tumors identified during laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2015;11:1025-28.
7. Finnell CW, Madan AK, Ternovits CA, Menachery SJ, Tichansky DS. Unexpected pathology during laparoscopic bariatric surgery. Surg Endosc. 2007;21:867-9.
8. Blay JY, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gas-trointestinal stromal tumors. Cancer. 2010;116:5126-37.
9. Greenbaum D, Friedel D. Unanticipated findings at bariatric surgery. Surg Obes Relat Dis. 2005;1:22-4.
10. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al. NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST) —update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw. 2007;5(Suppl.2):S1-29.
11. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw. 2010;8(Suppl.2):S1-41.
12. Steigen SE, Eide TJ. Gastrointestinal stromal tumors (GISTs): A review. APMIS. 2009;117:73-86.
13. Tryggvason G, Gislason HG, Magnusson MK, Jonasson J. Gastrointestinal stromal tumors in Iceland, 1990– 2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005;117:289-93.
14. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33:459-65.
15. Goettsch WG, Bos SD, Breekveldt-Postma N, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumors is underestimated: Results of a nation-wide study. Eur J Cancer. 2005;41:2868-72.
16. Zheng L, Wu X, Kreis ME, Yu Z, Feng L, Chen C, et al. Clinicopathological and immunohistochemical characterisation of gastric schwannomas in 29 cases. Gastroenterol Res Pract. 2014;2014:202960. doi: 10.1155/2014/202960.
17. Rubio J, Marcos-Gragera R, Ortiz MR, Miró J, Vilardell L, Gironès J, et al. Population-based incidence and survival of gastrointestinal stromal tumors (GIST) in Girona, Spain. Eur J Cancer. 2007;43:144-8.
18. Mullady DK, Tan BR. A multidisciplinary approach to the diagnosis and treatment of gastrointestinal stromal tumor. J Clin Gastroenterol. 2013;47:578-85.
19. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population based study in western Sweden. Cancer. 2005;103:821-9.
20. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Soft tissue sarcoma Version 2.2014. National Comprehensive Cancer Network. Fecha de consulta: 20 de junio de 2017. Disponible en: http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
21. Scherübl H, Faiss S, Knoefel WT, Wardelmann E. Management of early asymptomatic gastrointestinal stromal tumors of the stomach. World J Gastrointest Endosc. 2014;6:266-71.
22. Agaimy A, Vassos N, Croner RS. Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen’s disease): Clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol. 2012;5:852-62.
23. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217:72-7.
24. Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D, et al. Canadian advisory committee on GIST gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment. Can J Gastroenterol. 2006;20:157-63.
25. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23:427-36.
26. Raghavendra RS, Kini D. Benign, premalignant, and malignant lesions encountered in bariatric surgery. JSLS. 2012;16:360-72.
27. Yun HY, Sung R, Kim YC, Choi W, Kim H, Lee G, et al. Regional distribution of interstitial cells of Cajal (ICC) in human stomach. Korean. J Physiol Pharmacol. 2010;14:317-24.
28. Bhaskaran K, Douglas I, Forbes H, Dos Santos Silva, Leon D, Smeeth L, et al. Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5•24 million UK adults. Lancet. 2014;384:755-65.
29. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52-68.
30. Casali PG, Jost L, Reichardt P, Bielack S, Bjerkehagen B, Bonvalot S, et al. ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl.4):64-7.
31. Huang Z, Li Y, Zhao H, Zhao JJ, Cai JQ. Prognostic factors and clinicopathologic characteristics of small gastrointestinal stromal tumor of the stomach: A retrospective analysis of 31 cases in one center. Cancer Biol Med. 2013;10:165-8.